Giulia De Rossi

Dr. Giulia De Rossi

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
CCCarlotta Camilli
Carlotta Camilli
AHAlexandra Hoeh
Alexandra Hoeh
GRGiulia De Rossi
Giulia De Rossi
SMStephen E. Moss
Stephen E. Moss
John GreenwoodJohn Greenwood
John Greenwood
The secreted glycoprotein leucine-rich α-2 glycoprotein 1 (LRG1) was first described as a key player in pathogenic ocular neovascularization almost a decade ago. Since then, an increasing number of publications have reported the involvement of LRG1 in multiple human conditions including cancer, diabetes, cardiovascular disease, neurological disease, and inflammatory disorders. The purpose of this review is to provide, for the first time, a comprehensive overview of the LRG1 literature considering its role in health and disease. Although LRG1 is constitutively expressed by hepatocytes and neutrophils,Lrg1−/−mice show no overt phenotypic abnormality suggesting that LRG1 is essentially redundant in development and homeostasis. However, emerging data are challenging this view by suggesting a novel role for LRG1 in innate immunity and preservation of tissue integrity. While our understanding of beneficial LRG1 functions in physiology remains limited, a consistent body of evidence shows that, in response to various inflammatory stimuli, LRG1 expression is induced and directly contributes to disease pathogenesis. Its potential role as a biomarker for the diagnosis, prognosis and monitoring of multiple conditions is widely discussed while dissecting the mechanisms underlying LRG1 pathogenic functions. Emphasis is given to the role that LRG1 plays as a vasculopathic factor where it disrupts the cellular interactions normally required for the formation and maintenance of mature vessels, thereby indirectly contributing to the establishment of a highly hypoxic and immunosuppressive microenvironment. In addition, LRG1 has also been reported to affect other cell types (including epithelial, immune, mesenchymal and cancer cells) mostly by modulating the TGFβ signalling pathway in a context-dependent manner. Crucially, animal studies have shown that LRG1 inhibition, through gene deletion or a function-blocking antibody, is sufficient to attenuate disease progression. In view of this, and taking into consideration its role as an upstream modifier of TGFβ signalling, LRG1 is suggested as a potentially important therapeutic target. While further investigations are needed to fill gaps in our current understanding of LRG1 function, the studies reviewed here confirm LRG1 as a pleiotropic and pathogenic signalling molecule providing a strong rationale for its use in the clinic as a biomarker and therapeutic target.

1 November 2014 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
GRGiulia De Rossi
Giulia De Rossi
AEAlun R. Evans
Alun R. Evans
EKEmma Kay
Emma Kay
AWAbigail Woodfin
Abigail Woodfin
TMTristan R. McKay
Tristan R. McKay
JWJames R. Whiteford
James R. Whiteford
Angiogenesis is essential for the development of a normal vasculature, tissue repair and reproduction, and also has roles in the progression of diseases such as cancer and rheumatoid arthritis. The heparan sulphate proteoglycan syndecan-2 is expressed on mesenchymal cells in the vasculature and, like the other members of its family, can be shed from the cell surface resulting in the release of its extracellular core protein. The purpose of this study was to establish whether shed syndecan-2 affects angiogenesis. We demonstrate that shed syndecan-2 regulates angiogenesis by inhibiting endothelial cell migration in human and rodent models and, as a result, reduces tumour growth. Furthermore, our findings show that these effects are mediated by the protein tyrosine phosphatase receptor CD148 (also known as PTPRJ) and this interaction corresponds with a decrease in active β1 integrin. Collectively, these data demonstrate an unexplored pathway for the regulation of new blood vessel formation and identify syndecan-2 as a therapeutic target in pathologies characterised by angiogenesis.

28 July 2016 in Blood
Verified
Journal Article
Closed access
PDF file
DSDawn T. Smallwood
Dawn T. Smallwood
BABenedetta Apollonio
Benedetta Apollonio
SWShaun Willimott
Shaun Willimott
LLLarissa Lezina
Larissa Lezina
AAAfaf Alharthi
Afaf Alharthi
SWSimon D. Wagner
Simon D. Wagner
The complex interplay between cancer cells, stromal cells and immune cells in the tumor microenvironment (TME) regulates tumorigenesis and provides emerging targets for immunotherapies. Crosstalk between CD4+ T cells and proliferating chronic lymphocytic leukemia (CLL) tumor B cells occurs within lymphoid tissue pseudo-follicles and investigating these interactions is essential to understand both disease pathogenesis and the effects of immunotherapy. Tumor-derived extracellular vesicle (EV) shedding is emerging as an important mode of intercellular communication in the TME. In order to characterize tumor EVs released in response to T cell-derived TME signals, we performed microRNA (miR) profiling of EVs released from CLL cells stimulated with CD40 and IL-4. Our results reveal an enrichment of specific cellular miRNAs including miR-363 within EVs derived from CD40/IL-4 stimulated CLL cells compared to parental cell miRNA content and control EVs from unstimulated CLL cells. We demonstrate that autologous patient CD4+ T cells internalize CLL-EVs containing miR-363 that targets the immunomodulatory molecule CD69. We further reveal that autologous CD4+ T cells that are exposed to EVs from CD40/IL-4 stimulated CLL cells exhibit enhanced migration, immunological synapse signaling and interactions with tumor cells. Knockdown of miR-363 in CLL cells prior to CD40/IL-4 stimulation, prevented the ability of CLL-EVs to induce increased synapse signaling and confer altered functional properties to CD4+ T cells. Taken together, these data reveal a novel role for CLL-EVs in modifying T cell function that highlights unanticipated complexity of intercellular communication that may have implications for bidirectional CD4+ T-cell:tumor interactions within the TME.

1 January 2016
Verified
Book Chapter
Closed access
JWJ R Whiteford
J R Whiteford
GRGiulia De Rossi
Giulia De Rossi
AWA Woodfin
A Woodfin

9 January 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SASamantha Arokiasamy
Samantha Arokiasamy
MBMichaela J. M. Balderstone
Michaela J. M. Balderstone
GRGiulia De Rossi
Giulia De Rossi
JWJames R. Whiteford
James R. Whiteford
Syndecans are a four member multifunctional family of cell surface molecules with diverse biological roles. Syndecan-3 (SDC3) is the largest of these, but in comparison to the other family members relatively little is known about this molecule. SDC3 null mice grow and develop normally, all be it with subtle anatomical phenotypes in the brain. Roles for this molecule in both neuronal and brain tissue have been identified, and is associated with altered satiety responses. Recent studies suggest that SDC3 expression is not restricted to neuronal tissues and has important roles in inflammatory disorders such as rheumatoid arthritis, disease associated processes such as angiogenesis and in the facilitation of infection of dendritic cells by HIV. The purpose of this review article is to explore these new biological insights into SDC3 functions in inflammatory disease.

18 February 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
GRGiulia De Rossi
Giulia De Rossi
MVMaria Vähätupa
Maria Vähätupa
ECEnrico Cristante
Enrico Cristante
SASamantha Arokiasamy
Samantha Arokiasamy
SLSidath E. Liyanage
Sidath E. Liyanage
JWJames R. Whiteford
James R. Whiteford
Objective: VEGFA (Vascular endothelial growth factor A) and its receptor VEGFR2 (vascular endothelial growth factor receptor 2) drive angiogenesis in several pathologies, including diabetic retinopathy, wet age-related macular degeneration, and cancer. Studies suggest roles for HSPGs (heparan sulfate proteoglycans) in this process, although the nature of this involvement remains elusive. Here, we set to establish the role of the HSPG SDC4 (syndecan-4) in pathological angiogenesis. Approach and Results: We report that angiogenesis is impaired in mice null for SDC4 in models of neovascular eye disease and tumor development. Our work demonstrates that SDC4 is the only SDC whose gene expression is upregulated during pathological angiogenesis and is selectively enriched on immature vessels in retinas from diabetic retinopathy patients. Combining in vivo and tissue culture models, we identified SDC4 as a downstream mediator of functional angiogenic responses to VEGFA. We found that SDC4 resides at endothelial cell junctions, interacts with vascular endothelial cadherin, and is required for its internalization in response to VEGFA. Finally, we show that pathological angiogenic responses are inhibited in a model of wet age-related macular degeneration by targeting SDC4. Conclusions: We show that SDC4 is a downstream mediator of VEGFA-induced vascular endothelial cadherin internalization during pathological angiogenesis and a potential target for antiangiogenic therapies.